Start - Up Tial, which develops and sells an artificial intelligence (AI)-based pulmonary function tester, said on the 30th that it raised a total of 2.5 billion won in a Series A funding round from Capstone Partners, Hallym University·Technology Holdings, InfoBank, Korea Credit Guarantee Fund (KODIT), Digital Healthcare Partners (DHP), and Seoul Business Agency (SBA).
Tial's flagship product is the AI-based pulmonary function tester The Spirokit. It helps with early diagnosis of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). A key feature is that accurate pulmonary function and disease testing is possible even without a pulmonology specialist. Tial is expanding its product line with the Internet of Things (IoT)-enabled nebulizer The Neb and the inhaler aid spacer The Aerokit.
Chief Executive Kim Byeong-soo said, "Through this investment, we will further strengthen the productivity and distribution network of the products that have been launched," and added, "Along with performance upgrades to the existing The Spirokit, we expect the stable rollout of products currently under development, such as a fractional exhaled nitric oxide (FeNO) tester and a diffusing capacity of the lung for carbon monoxide (DLCO) tester."
Meanwhile, Tial is accelerating its push into overseas markets, including Vietnam, Indonesia, and the United States. Kim said, "By further solidifying our product pipeline, we will rise to become Korea's No. 1 respiratory specialist medical device company while also growing into a leading medical device company for respiratory care recognized around the world."